Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-50/CA209648: Nivolumab plus Ipilimumab or Nivolumab + Fluorouracil + Cisplatin vs Fluorouracil + Cisplatin in untreated advanced esophageal squamous cell carcinoma
jRCT2080223543Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of nivolumab and ipilimumab in Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenosquamous carcinoma (ASC) (3 arms), sponsored by Ono Pharmaceutical. Started May 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on jRCT2080223543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223543.